172 related articles for article (PubMed ID: 37016731)
1. An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain.
Mercadante S
Expert Opin Pharmacother; 2024 Feb; 25(2):171-179. PubMed ID: 37016731
[TBL] [Abstract][Full Text] [Related]
2. Cancer Pain Treatment Strategies in Patients with Cancer.
Mercadante S
Drugs; 2022 Sep; 82(13):1357-1366. PubMed ID: 36129661
[TBL] [Abstract][Full Text] [Related]
3. Treating breakthrough pain in oncology.
Mercadante S
Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
[TBL] [Abstract][Full Text] [Related]
5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
6. Breakthrough cancer pain in the radiotherapy setting: a systematic and critical review.
Mercadante S
Expert Rev Anticancer Ther; 2023 Mar; 23(3):229-234. PubMed ID: 36809181
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
8. Opioid and adjuvant analgesics: compared and contrasted.
Khan MI; Walsh D; Brito-Dellan N
Am J Hosp Palliat Care; 2011 Aug; 28(5):378-83. PubMed ID: 21622486
[TBL] [Abstract][Full Text] [Related]
9. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
[TBL] [Abstract][Full Text] [Related]
10. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
11. Opioids for Breakthrough Cancer Pain.
Currow DC; Clark K
Oncologist; 2020 Jul; 25(7):e1133. PubMed ID: 32400059
[TBL] [Abstract][Full Text] [Related]
12. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Mercadante S
Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
[TBL] [Abstract][Full Text] [Related]
13. Opioids in cancer-related pain: current situation and outlook.
George B; Minello C; Allano G; Maindet C; Burnod A; Lemaire A
Support Care Cancer; 2019 Aug; 27(8):3105-3118. PubMed ID: 31127436
[TBL] [Abstract][Full Text] [Related]
14. New drugs for pain management in advanced cancer patients.
Mercadante S
Expert Opin Pharmacother; 2017 Apr; 18(5):497-502. PubMed ID: 28276971
[TBL] [Abstract][Full Text] [Related]
15. Opioid dose titration for cancer pain.
Mercadante S
Eur J Pain; 2024 Mar; 28(3):359-368. PubMed ID: 37947151
[TBL] [Abstract][Full Text] [Related]
16. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
18. Opioid Use in Cancer Pain Management in Indonesia: a Call For Attention.
Setiabudy R; Irawan C; Sudoyo AW
Acta Med Indones; 2015 Jul; 47(3):244-50. PubMed ID: 26586391
[TBL] [Abstract][Full Text] [Related]
19. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project.
Zeppetella G
Palliat Med; 2011 Jul; 25(5):516-24. PubMed ID: 21708858
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
